A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene

Moon,Heegyum; Cho,Sunghee; Loh,Tiing   Jen; Zhou,Jianhua; Ghigna,Claudia; Biamonti,Giuseppe; Green,Michael  R.; Zheng,Xuexiu; Shen,Haihong

doi:10.3892/or.2013.2835

A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene

Authors:
- Heegyum Moon
- Sunghee Cho
- Tiing Jen Loh
- Jianhua Zhou
- Claudia Ghigna
- Giuseppe Biamonti
- Michael R. Green
- Xuexiu Zheng
- Haihong Shen
View Affiliations

Affiliations: School of life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Republic of Korea, Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, P.R. China, Institute of Molecular Genetics, National Research Council, I-27100 Pavia, Italy, Howard Hughes Medical Institute and Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
Published online on: November 5, 2013 https://doi.org/10.3892/or.2013.2835
Pages: 450-455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ron is a human receptor for the macrophage-stimulating protein (MSP). Exon 11 skipping of Ron pre-mRNA produces the Ron∆165 protein that has a deletion of a 49 amino acid region in the β-chain extracellular domain. Ron∆165 is constitutively active even in the absence of its ligand. Through stepwise deletion analysis, we identified a 2-nt RNA enhancer, which is located 74 nt upstream from the 5' splice site of exon 11, for exon 11 inclusion. Through double-base and single-base substitution analysis of the 2-nt RNA, we demonstrated that the GA, CC, UG and AC dinucleotides on exon 11, in addition to the wild-type AG sequence, function as enhancers for exon 11 inclusion of the Ron pre-mRNA.

View Figures

View References

1	Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 8:1195–1202. 1993.PubMed/NCBI
2	Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 12:273–281. 2005. View Article : Google Scholar : PubMed/NCBI
3	Gaudino G, Follenzi A, Naldini L, et al: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13:3524–3532. 1994.PubMed/NCBI
4	Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, et al: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer. 29:147–156. 2000. View Article : Google Scholar : PubMed/NCBI
5	Follenzi A, Bakovic S, Gual P, Stella MC, Longati P and Comoglio PM: Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 19:3041–3049. 2000. View Article : Google Scholar : PubMed/NCBI
6	Wang MH, Ronsin C, Gesnel MC, et al: Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 266:117–119. 1994. View Article : Google Scholar : PubMed/NCBI
7	Danilkovitch A and Leonard EJ: Kinases involved in MSP/RON signaling. J Leukoc Biol. 65:345–348. 1999.PubMed/NCBI
8	Longati P, Bardelli A, Ponzetto C, Naldini L and Comoglio PM: Tyrosines1234–1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene. 9:49–57. 1994.PubMed/NCBI
9	Iwama A, Yamaguchi N and Suda T: STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J. 15:5866–5875. 1996.PubMed/NCBI
10	Danilkovitch-Miagkova A: Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets. 3:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
11	Chen Q, Seol DW, Carr B and Zarnegar R: Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology. 26:59–66. 1997.PubMed/NCBI
12	Maggiora P, Marchio S, Stella MC, et al: Overexpression of the RON gene in human breast carcinoma. Oncogene. 16:2927–2933. 1998.
13	Wang MH, Yao HP and Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin. 27:641–650. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
15	Collesi C, Santoro MM, Gaudino G and Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 16:5518–5526. 1996.PubMed/NCBI
16	Ghigna C, Giordano S, Shen H, et al: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890. 2005. View Article : Google Scholar : PubMed/NCBI
17	Wahl MC, Will CL and Luhrmann R: The spliceosome: design principles of a dynamic RNP machine. Cell. 136:701–718. 2009. View Article : Google Scholar : PubMed/NCBI
18	Moore MJ and Proudfoot NJ: Pre-mRNA processing reaches back to transcription and ahead to translation. Cell. 136:688–700. 2009. View Article : Google Scholar : PubMed/NCBI
19	Han J, Xiong J, Wang D and Fu XD: Pre-mRNA splicing: where and when in the nucleus. Trends Cell Biol. 21:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
20	Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003. View Article : Google Scholar : PubMed/NCBI
21	Blencowe BJ: Alternative splicing: new insights from global analyses. Cell. 126:37–47. 2006. View Article : Google Scholar : PubMed/NCBI
22	Keren H, Lev-Maor G and Ast G: Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet. 11:345–355. 2010. View Article : Google Scholar : PubMed/NCBI
23	Grabowski PJ and Black DL: Alternative RNA splicing in the nervous system. Prog Neurobiol. 65:289–308. 2001. View Article : Google Scholar : PubMed/NCBI
24	David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lee J, Zhou J, Zheng X, et al: Identification of a novel cis-element that regulates alternative splicing of Bcl-x pre-mRNA. Biochem Biophys Res Commun. 420:467–472. 2012.
26	Cho S, Moon H, Yang X, et al: Validation of trans-acting elements that promote exon 7 skipping of SMN2 in SMN2-GFP stable cell line. Biochem Biophys Res Commun. 423:531–535. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kan JL and Green MR: Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor. Genes Dev. 13:462–471. 1999. View Article : Google Scholar : PubMed/NCBI
28	Shen H, Kan JL, Ghigna C, Biamonti G and Green MR: A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA. 10:787–794. 2004. View Article : Google Scholar : PubMed/NCBI